Skip to content

Sedation Compaired With Anesthesia With THRIVE in Endotracheal Intubation With Difficult Airways

Conventional Sedation Compaired With THRIVE Under General Anesthesia in Endotracheal Intubation by Fiberbronchoscope in Patients With Difficult Airways,A Randomized Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04924621
Enrollment
42
Registered
2021-06-14
Start date
2021-06-10
Completion date
2022-06-10
Last updated
2022-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedative, Hypnotic, or Anxiolytic Withdrawal, Airway Control

Keywords

Moderate Sedative, Airway Control, THRIVE

Brief summary

To compare the difference in endotracheal intubation in participants with difficult airway between under general anesthesia by Transnasal Humidified Rapid-Insufflation Ventilatory Exchange and under traditional sedation by mask ventilation. The investigators focus on the different outcomes in oxygenation maintaince, carbon dioxide removal and the effectiveness of safety apnea time, to evaluate the safety of receiving endotracheal intubation under general anesthesia in participants with difficult airway.

Interventions

DEVICERespiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.

The nasal cavity was disinfected with Iodophor cotton swab, and the appropriate nasal cavity was selected for endotracheal intubation assisted by fiberoptic bronchoscope according to the experience of anesthesiologists. After the endotracheal intubation was fixed, the anesthesia machine was connected for mechanical ventilation. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.

The Control Group will receive sequential intravenous infusion of Sufentanil 5ug, midazolam 0.05mg/kg, and propofol 1-2ug/ml, to make the BIS between 70 and 80. 2ml tetracaine was injected with cyclothyroid membrane puncture, and the nasal cavity was disinfected with iodophor cotton swab. According to the experience of anesthesiologists, the appropriate nasal cavity was selected for intranasal endotracheal intubation assisted by fiberbronchoscope. After the endotracheal intubation was successful, the anesthesia machine was connected for mechanical ventilation, full narcotic inducer will be injected. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.

DRUGMidazolam(T group)

Midazolam 0.05mg/kg, intravenous injection

DRUGSufentani(T group)

Sufentanil 0.02-0.05ug/kg, intravenous injection

DRUGPropofol(T group)

Propofol 2-3ug/ml, intravenous injection

DRUGRocuronium(T group)

Rocuronium 0.06mg/kg, intravenous injection

DRUGDrug use target(T group)

Make BIS \< 60 .

DRUGSufentanil(C group)

Sufentanil 5ug, intravenous injection

DRUGMidazolam(C group)

Midazolam 0.05mg/kg, intravenous injection

DRUGPropofol

Propofol 1-2ug/ml, intravenous injection

DRUGTetracaine(C group)

2ml tetracaine was injected with cyclothyroid membrane puncture.

DRUGDrug use target

Make the BIS between 70 and 80.

Sponsors

Peking University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-60 * Patients with difficult airway assessed by two anesthesiologists according to the difficult airway score who needed to undergo nasal endotracheal intubation for oral and maxillofacial surgery in Peking University Stomatological Hospital. * BMI between 18 to 30 kg/m2 * ASA Grade I to II * NYHA grade I * Patients requiring arterial hemodynamics monitoring and blood gas analysis due to surgical requirements * Signed the informed consent

Exclusion criteria

* Respiratory diseases: respiratory failure, COPD, pulmonary fibrosis, asthma and other diseases. Patients with ventilatory dysfunction or airway obstruction. * NYHA cardiac function grade greater than I, or NYHA cardiac function grade I but with a history of coronary heart disease. * Conditions affecting the monitoring of peripheral oxygen saturation, such as poor peripheral circulation perfusion and application of vasoconstrictor, are present. * Indoor oxygen saturation below 92%. * Patients who cannot tolerate rapid exchange ventilation with nasal humidification. * Patients with a history of easy nasal bleeding. * Inability to understand or express pain scores. * Menstrual period and lactation period of female patients. * The patient has mental illness. * Patients with severe intraoperative complications should be removed after surgery

Design outcomes

Primary

MeasureTime frameDescription
Blood oxygen pressureDay 0Blood oxygen pressure after intubation immediately.
Pulse oxygen saturationDay 0Pulse oxygen saturation after intubation immediately.
Blood carbon dioxide pressureDay 0Blood carbon dioxide pressure after intubation immediately.

Secondary

MeasureTime frameDescription
Tolerance of intubationDay 1The score of patient's tolerance to endotracheal intubation one day after surgery (0-10 points, 0 point is completely intolerable, 10 point is completely intolerable)
Time to complete intubationDay 0Time required to complete endotracheal intubation
Endtidal CO2Day 0Endtidal CO2 at time point of TA、TB、TC、TD
SPO2 below 92%Day 0Percentage of patients with pulse oxygen saturation below 92% during the trial
SPO2 below 95%Day 0Percentage of patients with pulse oxygen saturation below 95% during the trial
Success of intubationDay 0Proportion of successful endotracheal intubation
Arrhythmias or dramatic haemodynamic fluctuationsDay 0Arrhythmias and dramatic fluctuations in heart rate and blood pressure: types and times of arrhythmias in the test were recorded. Changes in heart rate and blood pressure more than 30% before surgery were recorded as dramatic fluctuations.

Countries

China

Contacts

Primary ContactXudong Yang, MD
kqyangxudong@163.com62179977

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026